Trial Profile
A Randomized, Controlled, Dose-finding, Observer-blind, Phase 2/3 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of CpG/Alum-adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccines (SCB-2019 Vaccine) in Children <18 Years of Age
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II/III
Latest Information Update: 27 Mar 2023
Price :
$35
*
At a glance
- Drugs SCB 2019 (Primary) ; Alum
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Clover Biopharmaceuticals
- 22 Mar 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 23 Aug 2022 Planned initiation date changed from 1 Jul 2022 to 1 Jan 2023.
- 27 Apr 2022 Planned initiation date changed from 1 Mar 2022 to 1 Jul 2022.